Kanrenol (Potassium Canrenoate)

Potassium canrenoate competitively blocks aldosterone at the mineralocorticoid receptor in the distal nephron. This inhibition reduces sodium reabsorption and potassium excretion, resulting in increased urinary sodium (natriuresis) and water loss, while retaining potassium, thereby decreasing extracellular fluid volume and vascular resistance.

The specific dose of Kanrenol is determined by the prescribing clinician based on the patient’s condition, severity, renal function, and response to therapy. Dosage adjustments are individualized, and the prescriber will provide detailed instructions on infusion rate and total daily amount.

Safety data for potassium canrenoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after careful assessment.

To request Kanrenol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kanrenol (potassium canrenoate) and spironolactone belong to the same aldosterone‑antagonist class, but potassium canrenoate is administered intravenously, offering rapid onset for acute settings, whereas spironolactone is an oral agent used for chronic management. Both share similar mechanisms and side‑effect profiles.

Kanrenol should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Inspect the solution for particulate matter or discoloration before use, and follow aseptic techniques during preparation.

Kanrenol is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and total daily volume are prescribed based on the clinical indication and patient response. Monitoring of vital signs and laboratory parameters is recommended during and after administration.

The most serious risks associated with Kanrenol include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, acute renal failure, marked hypotension, and rare anaphylactic reactions. Prompt recognition of symptoms such as muscle weakness, palpitations, or sudden drop in blood pressure is essential.

Kanrenol should be avoided in patients with known hypersensitivity to potassium canrenoate, existing hyperkalemia, severe renal impairment, or those receiving concurrent potassium‑supplementing therapies that could precipitate dangerous potassium elevations. Clinicians must evaluate each patient’s medical history before initiating therapy.